Download Free Medical Sedative-Hypnotic Drugs PowerPoint Presentation

Sedative-Hypnotic Drugs PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : Check out this medical PowerPoint presentation titled "Sedative-Hypnotic Drugs".

This medical PowerPoint presentation talks about sedative-hypnotic drugs. Sedative-hypnotic drugs are medications that are commonly used to treat anxiety, insomnia, and sleep disorders. They work by depressing the central nervous system, which can result in a calming or hypnotic effect.

There are several classes of sedative-hypnotic drugs, including benzodiazepines, nonbenzodiazepines, barbiturates, and other miscellaneous agents. Each class of drugs has its own unique properties and uses.

Tags : Sedative Drugs, Hypnotic Drugs, benzodiazepines, nonbenzodiazepines, barbiturates, Anesthesiology

Published on : Mar 17, 2023 | Views : 1169 | Downloads : 1

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

Sedative-Hypnotic Drugs By Bohlooli S, PhD School of Medicine, Ardabil University of Medical Sciences
Slide 2-

Dose-response curves for two hypothetical sedative-hypnotics
Slide 3-

BASIC PHARMACOLOGY OF SEDATIVE-HYPNOTICS CHEMICAL CLASSIFICATION Pharmacokinetics Pharmacodynamics
Slide 4-

CHEMICAL CLASSIFICATION: Benzodiazepines 1,4-benzodiazepines carboxamide group in the 7-membered heterocyclic ring structure A substituent in the 7 position, such as a halogen or a nitro group Barbiturates and other older drugs Several drugs with novel chemical structures Other classes of drugs antipsychotics , antidepressants , antihistaminics
Slide 5-

Chemical structures of benzodiazepines
Slide 6-

Chemical structures of barbiturates and other sedative-hypnotics
Slide 7-

Chemical structures of newer hypnotics
Slide 8-

Pharmacokinetics ABSORPTION AND DISTRIBUTION BIOTRANSFORMATION Benzodiazepines Barbiturates Newer hypnotics EXCRETION FACTORS AFFECTING BIODISPOSITION
Slide 9-

Biotransformation of benzodiazepines
Slide 10-

Pharmacokinetic properties of some benzodiazepines and newer hypnotics in humans
Slide 11-

Pharmacodynamics RAMELTEON BUSPIRONE MOLECULAR PHARMACOLOGY OF THE GABAA RECEPTOR NEUROPHARMACOLOGY BENZODIAZEPINE BINDING SITE LIGANDS ORGAN LEVEL EFFECTS
Slide 12-

RAMELTEON Melatonin receptors are thought to be involved in maintaining circadian rhythms underlying the sleep-wake cycle Ramelteon, a novel hypnotic drug prescribed specifically for patients who have difficulty in falling asleep Is an agonist at MT1 and MT2 melatonin receptors located in the suprachiasmatic nuclei of the brain. Adverse effects of ramelteon include dizziness, somnolence, fatigue, and endocrine changes as well as decreases in testosterone and increases in prolactin.
Slide 13-

BUSPIRONE Buspirone relieves anxiety without causing marked sedative, hypnotic, or euphoric effects. As a partial agonist at brain 5-HT1A receptors, No rebound anxiety or withdrawal signs on abrupt discontinuance. The anxiolytic effects of buspirone may take more than a week to become established The drug is used in generalized anxiety states but is less effective in panic disorders. The major metabolite is 1-(2-pyrimidyl)-piperazine (1-PP), which has alpha-2-adrenoceptor-blocking actions
Slide 14-

MOLECULAR PHARMACOLOGY OF THE GABAA RECEPTOR
Slide 15-

MOLECULAR PHARMACOLOGY OF THE GABAA RECEPTOR Assembled from five subunits Oolypeptide classes (a, b, g, d, e, p, r, etc). six different a, four b, and three g Two a1 and two b2 subunits and one g2 subunit Zolpidem, zaleplon, and eszopiclone bind more selectively: interact only with GABAA-receptor isoforms that contain a1 subunits
Slide 16-

NEUROPHARMACOLOGY GABA (gamma-aminobutyric acid) is the major inhibitory neurotransmitter The benzodiazepines do not substitute for GABA an increase in the frequency of channel-opening events Barbiturates also facilitate the actions of GABA to increase the duration of the GABA-gated chloride channel openings may also be GABA-mimetic depress the actions of excitatory neurotransmitters
Slide 17-

BENZODIAZEPINE BINDING SITE LIGANDS Agonists benzodiazepines Antagonists benzodiazepine derivative flumazenil Inverse agonists the b-carbolines
Slide 18-

ORGAN LEVEL EFFECTS Sedation Hypnosis Anesthesia Anticonvulsant effects Muscle relaxation Effects on respiration and cardiovascular function
Slide 19-

Sedation Calming effects Depressant effects on psychomotor and cognitive functions Dose-dependent anterograde amnesic effects
Slide 20-

Hypnosis Benzodiazepines the latency of sleep onset is decreased (time to fall asleep) the duration of stage 2 NREM sleep is increased the duration of REM sleep is decreased the duration of stage 4 NREM slow-wave sleep is decreased Zolpidem decreases REM sleep but has minimal effect on slow-wave sleep Zaleplon decreases the latency of sleep onset with little effect on total sleep time Eszopiclone increases total sleep time, mainly via increases in stage 2 NREM sleep
Slide 21-

Anesthesia Barbiturates thiopental and methohexital Benzodiazepines: diazepam, lorazepam, and midazolam a persistent postanesthetic respiratory depression reversible with flumazenil
Slide 22-

Anticonvulsant effects Benzodiazepines: clonazepam, nitrazepam, lorazepam, and diazepam Barbiturates: phenobarbital and metharbital Zolpidem, zaleplon, and eszopiclone lack anticonvulsant activity
Slide 23-

Muscle relaxation Members of the carbamate meprobamate Benzodiazepine groups Diazepam
Slide 24-

Effects on respiration and cardiovascular function Patients with pulmonary disease significant respiratory depression In hypovolemic states, heart failure, and other diseases cause cardiovascular depression
Slide 25-

Tolerance; Psychologic & Physiologic Dependence Tolerance partial cross-tolerance Mechanism An increase in the rate of drug metabolism down-regulation of brain benzodiazepine receptors Dependence relief of anxiety, euphoria, disinhibition, and promotion of sleep lead to misuse
Slide 26-

Physiologic Dependence States of Increased anxiety Insomnia central nervous system excitability The severity of withdrawal symptoms depends on: the magnitude of the dose relate in part to half-life Triazolam: daytime anxiety
Slide 27-

BENZODIAZEPINE ANTAGONISTS: FLUMAZENIL Competitive antagonists Blocks many of the actions of Benzodiazepines Zolpidem Zaleplon eszopiclone Reversing the CNS depressant effects Hasten recovery Flumazenil acts rapidly but has a short half-life May cause a severe precipitated abstinence syndrome
Slide 28-

CLINICAL PHARMACOLOGY OF SEDATIVE-HYPNOTICS TREATMENT OF ANXIETY STATES TREATMENT OF SLEEP PROBLEMS OTHER THERAPEUTIC USES
Slide 29-

TREATMENT OF ANXIETY STATES Secodary Anxiety States Secondary to organic disease Secondary to situational states as premedication Generalized anxiety disorder(GAD) Panic disorders Agoraphobia Acute anxiety states Panic attacks
Slide 30-

TREATMENT OF SLEEP PROBLEMS Sleep of fairly rapid onset Sufficient duration With minimal "hangover" effects Drowsiness Dysphoria Mental or motor depression
Slide 31-

Dosages of drugs used commonly for sedation and hypnosis
Slide 32-

Clinical uses of sedative-hypnotics
Slide 33-

CLINICAL TOXICOLOGY OF SEDATIVE-HYPNOTICS Direct Toxic Actions dose-related depression of the central nervous system Hypersensitivity reactions teratogenicity Alterations in Drug Response Tolerance Cross-tolerance Drug Interactions With other central nervous system depressant drugs hepatic drug-metabolizing enzyme systems